Characterization of the patterns of drug-resistance mutations in newly diagnosed HIV-1 infected patients naïve to the antiretroviral drugs

Table 2 Prevalence of resistant HIV-1 strains

Mutation^a	Prevalence			Infectious status
	Total^b		in combination^c	Long-standing Infection	Recent Infection
	All patients	Subtype B	N (%)	> 6 months (N = 197)	≤ 6 months (N = 58)	P-value ^d
	N (%/255)	N (%/213)
Major Drug resistance mutations
Any	15 (5.9)	15 (7.0)	9 (60.0)	13 (6.6)	2 (3.4)	0.09
NRTI
Any	10 (3.9)	10 (4.7)	8 (80.0)	8 (4.1)	2 (3.4)	1
Any TAM	7 (2.6)	7 (3.3)	7 (100)	6 (3.0)	1 (1.7)	1
Any TAM1	7 (2.6)	7 (3.3)	7 (100)	6 (3.0)	1 (1.7)	1
Any TAM2	1 (0.4)	1 (0.5)	1 (100)	0 (0.0)	1 (1.7)	0.2
M41L	4 (1.6)	4 (1.9)	4 (100)	3 (1.5)	1 (1.7)	1
D67N	1 (0.4)	1 (0.5)	1 (100)	0 (0.0)	1 (1.7)	0.2
T69D	1 (0.4)	1 (0.5)	0 (0.0)	0 (0.0)	1 (1.7)	0.2
M184V	1 (0.4)	1 (0.5)	1 (100)	1 (0.5)	0 (0.0)	1
L210W	6 (2.3)	6 (2.8)	6 (100)	5 (2.5)	1 (1.7)	1
T215Y	2 (0.8)	2 (0.9)	2 (100)	1 (0.5)	1 (1.7)	0.4
T215D/S	8 (3.1)	8 (3.8)	6 (75.0)	8 (4.1)	0 (0.0)	0.2
NNRTI
Any	9 (3.5)	9 (4.2)	5 (55.5)	8 (4.1)	1 (1.7)	0.7
L100I	2 (0.8)	2 (0.9)	2 (100)	2 (1.0)	0 (0.0)	1
K101E	2 (0.8)	2 (0.9)	0 (0.0)	2 (1.0)	0 (0.0)	1
K103N	7 (2.7)	7 (3.3)	5 (71.4)	6 (3.0)	1 (1.7)	1
P225H	1 (0.4)	1 (0.5)	1 (100)	1 (0.5)	0 (0.0)	1
PI
Any	1 (0.4)	1 (0.5)	1 (100)	1 (0.5)	0 (0.0)	1
L90M	1 (0.4)	1 (0.5)	1 (100)	1 (0.5)	0 (0.0)	1
Polimorphism at major resistance related positions
NNRTI
Any	8 (3.1)	8 (3.8)	1 (12.5)	7 (3.6)	1 (1.7)	0.69
K101Q/R	6 (2.3)	6 (2.8)	1 (16.7)	5 (2.5)	1 (1.7)	1
K103Q/R	3 (1.2)	3 (1.4)	1 (33.3)	3 (1.5)	0 (0.0)	1

^a Mutations that have been associated with transmitted drug resistance (Shafer et al., 2007) are reported.
^b Number (%) of drug resistance mutations.
^c Number (%) of drug resistance mutations that occurs in combination with other major mutations in a sequence. The percentages were calculated in patients containing each specific mutation.
^d Data were analyzed by using Fisher exact test.
Abbreviations: PI, protease inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; TAMs, thymidine analogue associated mutations

ISSN: 1471-2334